Acute and chronic effects of mixed nuts on energy metabolism in women at cardiometabolic risk: a randomized clinical trial.

Nutr Metab Cardiovasc DisMay 21, 2026 (epub)
Clinical ResearchEndocrinologyCardiology

Dandara B Bonifácio, Alessandra da Silva, Yuliana M F Estrada et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of mixed nuts on energy metabolism in women with overweight/obesity. The acute consumption of mixed nuts significantly increased postprandial fat oxidation (piAUC: 47.53 ± 5.78 mg/min vs. 27.93 ± 6.98 mg/min; p = 0.048). However, chronic intake alongside an energy-restricted diet did not significantly alter energy metabolism markers after 8 weeks.

Key findings

  • Acute mixed nuts consumption increased postprandial fat oxidation compared to control.
  • Fat oxidation was 47.53 ± 5.78 mg/min in the mixed nuts group versus 27.93 ± 6.98 mg/min in the control group.
  • Chronic intake of mixed nuts did not significantly change fasting fat oxidation after 8 weeks.

Why it matters

Understanding the impact of dietary components like mixed nuts on energy metabolism can inform dietary recommendations for women at cardiometabolic risk, particularly in managing weight and metabolic health.

Source

PubMed · PMID 42218065

Published in Nutr Metab Cardiovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.